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In Brief
Interferon a (IFNa) and IFNb utilize the
same type I IFN receptor to regulate
immune responses against microbial
infection. Ng et al. show in vivo that IFNb
and IFNa have differential roles in
controlling a persistent viral infection, and
that IFNb is the major factor responsible
for causing viral persistence.
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Although type I interferon (IFN-I) is thought to be
beneficial against microbial infections, persistent
viral infections are characterized by high interferon
signatures suggesting that IFN-I signaling may pro-
mote disease pathogenesis. During persistent lym-
phocytic choriomeningitis virus (LCMV) infection,
IFNa and IFNb are highly induced early after infec-
tion, and blocking IFN-I receptor (IFNAR) signaling
promotes virus clearance. We assessed the specific
roles of IFNb versus IFNa in controlling LCMV infec-
tion. While blockade of IFNb alone does not alter
early viral dissemination, it is important in deter-
mining lymphoid structure, lymphocyte migration,
and anti-viral T cell responses that lead to acceler-
ated virus clearance, approximating what occurs
during attenuation of IFNAR signaling. Compara-
tively, blockade of IFNa was not associated with
improved viral control, but with early dissemination
of virus. Thus, despite their use of the same receptor,
IFNb and IFNa have unique and distinguishable bio-
logic functions, with IFNb being mainly responsible
for promoting viral persistence.
INTRODUCTION
Type I interferon (IFN-I) is a key element in the innate and adap-
tive response against host infection. Important functions of this
family of cytokines include inducing an antimicrobial state,
moderating innate immunity, and activating adaptive immunity.
Although IFN-Is have generally been thought to be beneficial
to the immune response against microbial infections, recent
research has shown that IFN-I signaling may be detrimental in
several pathogenic infections (Davidson et al., 2014; Harris
et al., 2010; Mayer-Barber et al., 2014; Teijaro et al., 2013; Teles
et al., 2013; Wilson et al., 2013). Further, persistent viral infec-
tions such as HIV, SIV, and HCV are characterized by high inter-
feron signatures suggesting that high levels of IFN-I signaling
may play a role in disease pathogenesis (Bolen et al., 2013;
Hardy et al., 2013; Sedaghat et al., 2008; Stylianou et al.,Cell H2000). Previously, we reported that blockade of IFN-I signaling
led to the accelerated clearance of persistent infection with the
clone 13 (Cl-13) strain of lymphocytic choriomeningitis virus
(LCMV) (Teijaro et al., 2013). IFN-I signaling was associated
with several factors that correlated with an immune-suppressive
environment including the following: (1) induction of negative im-
mune regulators (NIRs) interleukin-10 (IL-10) and programmed
death ligand-1 (PD-L1), (2) disruption of splenic architecture,
and (3) alteration of lymphocyte migration within the spleen.
Blockade of IFN-I signaling corrected these defects, resulting
in improved viral control. Although the IFN-I pathway was identi-
fied as a master regulatory pathway involved in persistent LCMV
infection, it is unknown whether a specific species of IFN-I is
responsible for these phenomena.
The IFN-I family consists of a dozen IFNa subtypes, IFNb, as
well as IFNε, IFNu, and IFNk, which are induced after the detec-
tion of pathogens by pattern-recognition receptors. All IFN-I uti-
lize the same heterodimeric receptor composed of IFNAR1 and
IFNAR2; however, IFN-I subtypes have different signaling activ-
ities. Structured analysis has revealed that functional differences
between IFNs are linked to their unique receptor binding
strengths and dissociation rates, which combine to determine
their ability to induce conformational change in the receptor.
These ultimately control signal generation and downstream
gene expression (Piehler et al., 2012; Thomas et al., 2011).
Importantly, IFNb has the highest binding affinity of the IFN-I
family (Piehler et al., 2012).
The LCMV Cl-13 virus induces a persistent viral infection in
adult immunocompetent mice (Ahmed and Oldstone, 1988; Old-
stone, 2002; Oldstone and Campbell, 2011). During Cl-13 infec-
tion, IFNb is produced at high levels within the first 18–24 hr after
infection. Comparatively, only a minimal amount is detected dur-
ing infection with the Armstrong 53b (ARM) strain of LCMV,
which only differs by three amino acids from Cl-13, but causes
an acute infection (Bergthaler et al., 2010; Sullivan et al., 2011).
IFNa is detected in both Cl-13 and ARM infection; however,
Cl-13 infection induces approximately 3-fold more IFNa (Teijaro
et al., 2013). The presence of robust levels of IFNb during infec-
tion with Cl-13 and its relative absence during ARM infection
suggests that IFNb may play a major role in IFN-I mediated viral
persistence. Based on these observations, we sought to deter-
mine the in vivo contribution of IFNb, as well as IFNa, to persis-
tent LCMV infection using deletion mutants and antibody
blockade. We found that early blockade of IFNb alone doesost & Microbe 17, 653–661, May 13, 2015 ª2015 Elsevier Inc. 653
Figure 1. IFNb Is Not Responsible for Preventing Viral Spread in the First 24 hpi
(A–D) WT, ifnb/, and ifnar/mice were infected with 23 106 plaque-forming units (pfu) of LCMV Cl-13 virus. Tissues were harvested at 24 hpi to examine (A)
virus localization in the spleen by immunofluorescent microscopy and (B–D) infection of DCs and macrophage/monocytes by flow cytometry.
(legend continued on next page)
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Figure 2. IFNb Contributes to Disruption of
Splenic Architecture
C57BL/6 mice were intraperitoneally given irrele-
vant IgG, anti-IFNb, or anti-IFNAR1 1 day before
infection with Cl-13. At 5 and 9 dpi, spleens were
harvested and either fluorescently stained for
LCMV antigen (green) andMOMA-1 to define white
pulp margins (red) (A–F), stained for H&E to
examine histology (G–I), or immunofluorescently
stained for CD3 to identify T cells (red) and ER-TR7
to delineate splenic stromal structure (green) (J–L).not alter early viral dissemination, but, most importantly, initiates
events that lead to accelerated clearance of virus. Thus, we pro-
vide a biologic complement to the known physio-chemical differ-
ence between IFNa and IFNb signaling (Piehler et al., 2012;
Thomas et al., 2011).
RESULTS
IFNb Does Not Inhibit Early In Vivo Spread of Infection
To examine the establishment of infection, we used mice in
which the ifnb gene had been deleted (ifnb/) to ensure com-
plete lack of signaling from IFNb. In wild-type (WT) mice, at
24 hr post-infection (hpi), virus is observed predominantly in
themarginal zone. When IFN-I signaling is completely abrogated
(ifnar/), virus demonstrated spread beyond the marginal zone
at 24 hpi (Figure 1A) corresponding with the inhibition of IFN-I
anti-viral functions. Comparatively, ifnb/ mice at 24 hpi did
not exhibit differences in the localization of the virus. This
same trend was also observed in the levels of infection in den-
dritic cell (DC) and macrophage/monocyte populations (Figures
1B and 1C), which are both targets of Cl-13 infection. DCs and
macrophage/monocyte populations in ifnar/ mice exhibited(E–I) WT C57Bl/6 mice were intraperitoneally administered anti-IFNAR1, anti-IFNb, or IgG control antibody 1 d
of infected CD8a+ DCs, CD8aDCs, and macrophage/monocytes; (F) the proportion of the population infect
in infected cells as measured by mean fluorescent intensity were assessed at 24 hpi by flow cytometry. (H) V
IFNb (I) wasmeasured in the serumby ELISA to test for possible alterations in expression due to antibody bloc
**p < 0.01, ***p < 0.001.
Cell Host & Microbe 17, 653–significantly higher levels of infection
than WT mice. Cells that were infected
also demonstrated higher numbers and
higher levels of viral protein as assessed
by levels of LCMV nucleoprotein (NP)
staining (Figures 1D–1G). These two pop-
ulations in ifnb/mice did not exhibit any
increase in infection from WT mice as
similar numbers and percent of infected
cells were noted (Figures 1B and 1C),
although there was an increase in the
mean fluorescent intensity (MFI) of NP
staining within infected DCs (ifnb/,
8,774.6 ± 2,414.6 versus WT, 4,903.2 ±
2,414.6; p > 0.005). To ensure that these
observations were not due to abnormal
development in the mutant mice, we also
examined WT B6 mice treated with anti-IFNAR and anti-IFNb antibodies 1 day before infection. Here,
the same observations were repeated. Anti-IFNb-treated mice
did not exhibit any increase in the number or percentage of cells
expressing viral antigen in the main subsets of DCs, CD8a+ and
CD8a, or macrophages/monocytes at 24 hpi (Figures 1D and
1E). Nor did infected DCs of anti-IFNb-treated mice exhibit
higher MFI levels of viral NP expression. Viral titers in total spleen
tissue and serum at 24 and 48 hpi also did not demonstrate
significant increases in titers in anti-IFNb compared to isotype
controls, while anti-IFNAR treated mice exhibited significantly
higher titers in both compartments (Figure 1H). The similarity in
infection of antigen-presenting cells between IgG-treated and
anti-IFNb-treated mice was likely due to the continued presence
of IFNa, as these groups had equivalent levels in the serum
(Figure 1I). As expected, when anti-IFNAR was used to block
all IFN-I signaling, DCs and macrophage/monocytes were in-
fected at higher rates in anti-IFNAR-treated mice compared to
IgG-treated controls (Figures 1E and 1F). Examination of viral an-
tigen in spleen tissues after the establishment of infection at 5
and 9 dpi (Figures 2A–2F) also revealed little difference in general
localization of virus. These data demonstrate that IFNb is not
essential for early anti-viral activity and does not alter later viralay before infection with Cl-13 virus. (E) The number
ed; and (G) the relative level of LCMV nucleoprotein
iral load in serum and spleen. The level of IFNa and
kade. Data are presented asmean ± SEM; *p < 0.05,
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localization, suggesting that IFNa is primarily responsible for
the IFN-mediated anti-viral activity during early dissemination
in vivo.
IFNb Contributes to Disruption of Splenic Architecture
Cl-13 infection results in the disorganization of secondary
lymphoid tissue and disordered lymphocyte trafficking, factors
that play a role in the observed globalized immune suppression
(Berger et al., 1999; Mu¨ller et al., 2002; Odermatt et al., 1991;
Tishon et al., 1993; Zeng et al., 2011). This phenotypewas readily
apparent in the spleen as evidenced by the destruction of mar-
ginal zones and white pulp, which left little delineation between
white pulp and red pulp shown by heavy hematoxylin staining
across the entire spleen at 9 dpi (Figure 2G). Blockade of IFNAR
signaling by antibody (Figure 2I; Teijaro et al., 2013) or gene
deletion (data not shown) resulted in protection from this
disorganization. Blockade of IFNb alone offered protection
from Cl-13-mediated disorganization, with spleens from anti-
IFNb-treated mice exhibiting more defined white pulp compared
to control spleens (Figure 2H). Thus, aborting IFNb signaling re-
sults in a higher concentration of lymphocytes in the white pulp.
This is further demonstrated by examining T cell zones, which
are highly disturbed in normal Cl-13 infection (Figure 2J; Teijaro
et al., 2013). When IFNAR signaling is blocked, T cell zones and
white pulp remain intact (Figure 2L; Teijaro et al., 2013) poten-
tially maintaining efficient DC-T cell interactions to better facili-
tate T cell activation. Under anti-IFNb treatment, T cells remained
localized at higher densities to the white pulp when compared to
isotype controls (Figure 2K). Images depicted in Figure 2 are
representative of spleen histology from 10 to 15 mice for each
antibody treatment over three to four independent studies with
analysis of greater than five independent areas of each splenic
section.
IFNb Blockade Alters Virus-Specific Immune Responses
Previously, we showed that treatment of Cl-13-infected mice
with anti-IFNAR antibody improved anti-LCMV CD4 T cell re-
sponses, but not CD8 T cell responses, at 5 and 9 dpi (Teijaro
et al., 2013). Here, we blocked IFNb alone, and at 9 dpi observed
similar significant improvements in the number of LCMV glyco-
protein (GP)61-77-specific IFNg
+ CD4 T cells and improve-
ments in IFNg+TNFa+ CD4 T cells (Figure 3A). Importantly,
anti-IFNb-treated mice also exhibited increases in the number
of anti-LCMV CD8 T cells at 9 dpi. The IFNb blockade
resulted in a significant 2-fold increase in GP33-41-specific and
NP396-403-specific IFNg
+ CD8 T cells over isotype control-
treated mice and a significant 1.5-fold increase in IFNg+TNFa+
CD8 T cells (Figure 3B). Although higher variability occurred
when the number of GP61-77-specific CD4 T cells and GP33-41-
specific CD8 T cells was assessed by tetramer staining, similar
trends were observed (Figure 3C). The improvement in anti-
LCMV T cell responses during IFNb blockade at these time
points was not due to a reduction in immunodominant NIRs
PD-L1 and IL-10, which have both been shown to contribute
to Cl-13 persistence (Barber et al., 2006; Brooks et al., 2006,
2008) and are decreased in IFNAR blockade (Figures 3D and
3E; Teijaro et al., 2013). There were no significant differences
in cell surface expression of PD-L1 on antigen-presenting cells
and splenic stromal cells of anti-IFNb-treated mice at 9 dpi (Fig-656 Cell Host & Microbe 17, 653–661, May 13, 2015 ª2015 Elsevier Iure 3D) or early on at 1 dpi (data not shown). Similarly, serum
levels of IL-10 in anti-IFNb-treated mice were also comparable
to controls at 9 dpi (Figure 3E) and at 1 dpi (data not shown).
These differences were no longer significant at 15 (Figure S1)
and 40 dpi (data not shown). These data suggest that blocking
IFNb signaling permits improved T cell activity, but as infection
continues and antibody to IFNAR or IFNb wanes, T cell activity
resembles control-treated mice.
IFNbBlockade, but Not IFNaBlockade, Accelerates Viral
Clearance
To test if these observed differences mediated the contribution
of IFNb to IFN-I-mediated viral persistence, we treatedmice with
anti-IFNb and followed the mice longitudinally to test viremia in
sera and tissues over time. We also tested the involvement of
IFNa by administering an anti-IFNa antibody that has been
shown to neutralize six IFNa subtypes (A, 1, 4, 5, 11, and 13).
At 10 and 20 dpi (Figure 3F), blockade of either IFN alone did
not exhibit any significant differences in viral titer. Anti-IFNAR-
treated mice exhibited slightly higher viral loads at 10 dpi and
begin to decrease by 20 dpi as observed previously. At 30 dpi,
viral titers decreased significantly in mice treated with anti-
IFNb and anti-IFNAR compared to control mice, while no differ-
ences were observed in anti-IFNa-treated mice (Figure 3F).
The decrease in serum viral load was greater in anti-IFNAR-
treated mice (1.8 log10) compared to anti-IFNb-treated mice
(0.8 log10). At 40 dpi (Figure 3G) viral load in spleen, liver,
lung, and serum was significantly reduced in anti-IFNb- and
anti-IFNAR-treated mice compared to anti-IFNa- or isotype con-
trol-treated mice. Clearance in the anti-IFNb-treated mice was
not due to an increase or decrease in IFNa production, as these
mice had serum levels equivalent to control mice at 24 hpi when
anti-IFNb antibody levels are highest (Figure 1I). Real-time PCR
assessment of mRNA expression of the 12 IFNa subtypes also
did not reveal any significant alterations in the proportion of
each subtype expressed between anti-IFNb- and isotype con-
trol-treated mice (data not shown). Because the anti-IFNa anti-
body is only known to neutralize six subtypes of IFNa, we cannot
rule out the participation of other IFNa subtypes in persistence.
However, our results clearly show the involvement of IFNb in
Cl-13 persistence.
Blockade of IFNb and IFN-I Signaling Decreases
CD8a–DC Viral Load
Productive infection of DCs is necessary to maintain Cl-13
persistence (Popkin et al., 2011), and, hence, a reduction of
the population of DCs producing virus may contribute to early
viral clearance. CD8aDCs are the predominant subtype of
conventional DCs that are infected (Ng and Oldstone, 2012),
although limited infection occurs in the smaller CD8a+ DC
population. Accordingly, we examined both these DC popula-
tions to determine if IFN-I blockade altered infection of the
conventional DC population. Since the peak serum viral load
and peak of DC infection is between 7 and 10 dpi (Sevilla
et al., 2003), we measured DC infection at 7 dpi in anti-IFNb-
and anti-IFNAR-treated mice to determine whether these
mice better controlled infection in this population at a critical
time point. At 7 dpi, infection of total splenocytes was slightly
elevated in anti-IFNb-treated mice and significantly greater innc.
Figure 3. Blockade of IFNb Results in Improved T Cell Responses at 9 dpi and Accelerates Clearance of Persistent LCMV Infection
The spleens or antibody-treated mice infected with 2 3 106 pfu LCMV Cl-13 were harvested at 9 dpi to measure anti-LCMV T cell responses.
(A) IFNg, TNFa, and IL-2 expression in CD4 T cells stimulated with LCMV CD4 epitope GP61-77.
(B) IFNg, TNFa, and IL-2 expression in CD8 T cells stimulated with either GP33-41 or NP396-403.
(C) Number of GP61-77 tetramer+ CD4 T cells and GP33-41 tetramer+ CD8 T cells.
(D) Cell surface expression of PD-L1 on antigen-presenting cells and stromal cells.
(E) Levels of IL-10 in the serum were measured by ELISA.
(F and G) IgG or antibody against IFNb, IFNa, or IFNAR were administered intraperitoneally 1 day before infection with 2 3 106 pfu LCMV Cl-13.
(F) Viral load in the serum was assessed at 10, 20, and 30 dpi.
(G) Viral load in spleen, liver, lung, and serum was quantitated at 40 dpi. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.anti-IFNAR-treated mice compared to isotype-treated mice
(Figure 4A). This pattern was matched in the CD8a+ DC popula-
tion (Figure 4B). However, CD8aDC population, which makes
up the majority of classical DC population, exhibited signifi-
cantly lower percentages of infection in both anti-IFNb- and
anti-IFNAR-treatedmice (Figure 4B). To better ascertain whether
the reduction in CD8aDC infection was due to T cell responses,
we examined the DC population at 4 dpi before T cell responses
have peaked. DC infection at this earlier time point revealed
similar trends to 7 dpi (Figure S2). These data suggest that
despite higher infection rates in the overall spleen, as well as
serum, during IFNb and IFNAR blockade, the infection rates in
CD8aDC, a target population, are controlled, despite being
higher at the initiation of infection (Figure 1).Cell HDISCUSSION
We, and others, previously established the IFN-I signaling
pathway as a master regulator of viral persistence (Teijaro
et al., 2013; Wilson et al., 2013), thereby redefining the paradigm
of IFN-I as an exclusively host-protective, anti-viral cytokine dur-
ing viral infection. There are 16 members of the IFN-I family that
all generate their activities via the same receptor and JAK/Stat
signaling pathway, yet they induce differing activity profiles.
LCMV Cl-13 and ARM elicit differing levels of IFNa and IFNb,
but differ by three amino acids, of which only two determine
whether the virus causes an acute or persistent infection
(Bergthaler et al., 2010; Lee et al., 2013; Sullivan et al., 2011).
Previous comparison of IFN-I levels of LCMV Cl-13, whichost & Microbe 17, 653–661, May 13, 2015 ª2015 Elsevier Inc. 657
Figure 4. Blockade of IFN-I Signaling De-
creases Rates of Infection in CD8a–DCs
C57BL/6 mice were treated with IgG, anti-IFNb, or
anti-IFNAR1 1 day before infection with Cl-13. At
7 dpi, the presence of LCMV NP was assessed
by flow cytometry in the splenocytes (A) and
CD8a+ and CD8aDCs (B). Data are presented as
mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001.sets up a persistent infection, with the closely related ARM infec-
tion, which does not induce a persistent infection in immuno-
competent mice, demonstrated that Cl-13 preferentially elicits
higher levels of IFNb than ARM at 18–24 hpi. This suggested a
role for IFNb in mediating persistent LCMV infection. Our study
demonstrates that specific abrogation of IFNb recapitulates the
accelerated viral clearance obtained by IFN-I receptor blockade.
Total IFNa is elicited at > 10-fold-higher levels than IFNb at 24 hpi
(Figure 1I; Teijaro et al., 2013), but only abrogation of IFNb
signaling altered the kinetics for clearance of Cl-13 infection.
Thus, blockade of at least six subspecies of IFNa did not result
in differences in infection clearance, restoration of splenic archi-
tecture, or T cell activity. Blockade of IFNb did not alter early viral
dissemination, demonstrating that this cytokine is not vital to
control early viral replication and complements other studies
showing that early IFNa is important in managing viral spread
(Sandler et al., 2014; Sullivan et al., 2015). Though IFNb did not
alter early viral dissemination, the influence of IFNb was mark-
edly pronounced in later events. Anti-IFNb treatment signifi-
cantly aborted lymphoid architecture disruption and dissolution
of T cell zones, both hallmarks of persistent Cl-13 infection
and other chronic viral infections. This indicates that IFNb
signaling is detrimental to lymphoid structure and lymphocyte
trafficking. Due to the strong association between lymphoid
structure and T cell response, IFNb-generated changes likely
impede efficient anti-viral T cell responses. Indeed, at 9 dpi
when T cell exhaustion has already been established during
Cl-13 infection, early anti-IFNb treatment generated an anti-
LCMV CD4 response greater than those of control mice. IFNb
blockade also generated greater CD8 T cell responses than iso-
type control-treated mice with greater numbers of IFNg+ CD8
T cells than observed with anti-IFNAR treatment, despite IL-10
and PD-L1 levels that were equivalent to control mice. Although
increased T cell responses were transient, individual animals in
the anti-IFNb group remained high at 15 dpi suggesting some
level of disassociation between the dominant immune regulators
IL-10 and PD-L1, which were not reduced by IFNb blockade. A
similar example of vigorous anti-viral CD8 T cell responses in
the presence of heightened IL-10 and PD-1/PD-L1 has recently
been reported in acute LCMV infection of NZB mice (Baccala
et al., 2014). It is possible that other negative regulatory factors
like TIM-3 (Jin et al., 2010; Sakuishi et al., 2011) or NK cell activity
(Waggoner et al., 2012) were decreased and, thus, contributed to
the increased T cell responses. Recently it has been described
that IFNAR1 signaling on CD8 T cells targets them for NK cell-
mediated destruction (Xu et al., 2014). Previous publications
have also linked T cell suppression to antigen load (Mueller658 Cell Host & Microbe 17, 653–661, May 13, 2015 ª2015 Elsevier Iand Ahmed, 2009; Richter et al., 2012). However, it is clear
from our data and from previous studies of IFN-I blockade (Bac-
cala et al., 2014; Teijaro et al., 2013; Wilson et al., 2013) that this
association is not absolute and as shown here can be uncoupled
by disrupting IFNb signaling.
Although blockade of IFNa using the monoclonal antibody
TIF-3C5 did not elicit better control of viremia compared to
IgG-isotype control-treated mice (Figures 3F and 3G), we cannot
completely rule out some contribution by IFNa (or other forms of
IFN-I) in viral persistence. The TIF-3C5 antibody neutralizes at
least six subtypes of IFNa and, importantly, is able to neutralize
significant amounts of IFNa in vivo to alter viral infection. TIF-3C5
antibody enhances susceptibility of both WT and IFNb/ mice
during infection with West Nile virus and results in increased
lethality (K.C.F.S., H.M. Lazear, M.S. Diamond, and R.D.S., un-
published data). In our model, the antibody was administered
2 days before the peak of IFNa production (antibody given at
1 dpi with IFNa peak at 18–48 hpi). Hence, it is most likely
that a majority of IFNa was neutralized between the 18 and
48 hpi when IFNa levels are highest. Further, even in the pres-
ence of high levels of IFNa, antibody to IFNb mediated viral
control with a kinetic similar to that observed with anti-IFNAR
antibody reinforcing the hypothesis that IFNa is not a major
mediator of viral persistence.
The specific mechanism(s) by which IFN-I blockade, and spe-
cifically IFNb blockade, mediates viral clearance is uncertain. A
component is likely dependent on CD4 T cells (Osokine et al.,
2014; Teijaro et al., 2013) and DC infection (Popkin et al.,
2011). Our data suggest that control of infection in the DC is
potentially an important factor in the early control of persistent
infection observed in anti-IFNb- and anti-IFNAR-treated mice.
CD8aDCs, which compose 75% of the conventional DC
population, are infected at decreased rates in anti-IFNb- and
anti-IFNAR-treated mice at 7 dpi when serum viral load and total
splenocyte infection rates are higher than isotype controls. At
4 dpi, infection in CD8aDCs was lower in anti-IFNb-treated
mice, but not anti-IFNAR-treated mice, which may be due to
the much higher initial viral load in these mice. It is well estab-
lished that DCs are a main target of Cl-13 infection (Lee et al.,
2013; Oldstone and Campbell, 2011; Sevilla et al., 2000, 2003),
that functionally active LCMV-specific T cells can lyse virus-in-
fected DCs (Borrow et al., 1995), and that preventing or limiting
productive infection of this population permits early resolution
of the persistent infection (Popkin et al., 2011). Consequently,
decreasing rates of DC infection may lead to a decrease in
viremia that is then more quickly controlled by the host immune
response. A lower rate of DC infection would also result in anc.
greater proportion of ‘‘healthy’’ DCs to initiate and maintain anti-
LCMV T cell immunity as infected DCs have decreased cell sur-
face expression of MHCII and co-stimulatory molecules CD80
and CD86 (Sevilla et al., 2003). We are currently exploring two-
photon analysis of DC-T cell interactions during Cl-13 infection
and analyzing the effect of early abrogation of IFNb and IFN-I
signaling.
Here we show that high expression of IFNb in vivo is advanta-
geous to the virus LCMV. However, LCMV is able to block IFNb
expression in vitro (Martı´nez-Sobrido et al., 2006), and exoge-
nous administration of IFN-I (both IFNb and IFNa5) 3–5 dpi can
rescue CD8 T cell responses (Wang et al., 2012). These dichot-
omous observations are likely due to an association between ef-
fect andmagnitude and timing of signaling and in vitro conditions
compared to in vivo studies. A recent study in SIV-infected ma-
caques demonstrates that timing of IFN-I is an important factor in
determining whether IFN-I signaling is beneficial or detrimental
(Sandler et al., 2014). Timing may involve not just the timing of
the IFN-I family as a whole, but the timing of different subtypes.
Each IFN-I subtype may have overlapping, but unique, windows
during which the subtype’s specific signaling may best generate
a beneficial effect. The timing of early events is likely key as over-
coming early innate signals is important to the establishment of
persistence (Sullivan et al., 2015). Priming mice with LCMV just
before infection with CL-13 decreases the virus’s ability to
generate a battery of early cytokines, including IFNa, IFNb, and
IL-10, as well as abrogating the virus’s ability to persist. Signaling
magnitude is also likely a factor as blockade of IFNAR1 via an
antibody produces accelerated viral clearance (Teijaro et al.,
2013; Wilson et al., 2013), while deletion of the gene results in
the inability to clear the virus. Coupled with IFN-I levels observed
during ARM infection, these data suggest that there is a range of
signaling below which signaling is not sufficient to generate im-
munity and above which the overwhelming signal becomes
detrimental to immunity (i.e., zero/low signaling will not protect,
while high levels of signaling will lead to downregulation of immu-
nity and persistence).
In summary, there are more than a dozen different subtypes of
IFN-I. Although there are certainly functional overlaps, it is
unlikely that evolution would select for such a wide variety of
IFN-I proteins unless each one fulfilled unique functions or roles
during different types of immune responses. Our data indicate
that of the IFN-I cytokines, IFNb is the major immune-suppres-
sive cytokine during viral infection that inhibits viral clearance.
There are several published examples of the immune-suppres-
sive activity of IFNb. In multiple sclerosis, treatment with IFNb
reduces the relapse rate, severity, and progression of this auto-
immune disease (The IFNB Multiple Sclerosis Study Group and
The University of British Columbia MS/MRI Analysis Group,
1995) by eliciting anti-inflammatory cytokines such as IL-10 (By-
rnes et al., 2002; Rudick et al., 1996; Yong et al., 1998) and
potentially restricting T cell proliferation (Yong et al., 1998). In
the murine model of cerebral malaria, IFNb treatment reduces
disease severity and prolongs survival by reducing T cell recruit-
ment to the brain (Morrell et al., 2011). These examples coupled
with the previous known functions of IFNb as an inducer of IFNa
(Koch et al., 2005), an anti-viral cytokine, and modulator of
lymphocyte activity, serve to highlight IFNb’s role as a master
regulator of immune function.Cell HThe accumulation of data documenting immune-suppressive
and detrimental effects of IFN-I indicate that not only are the
effects of these cytokines complex, but careful mapping of their
activity and receptor binding coupled with development of ther-
apeutic molecules may also open new avenues for treatment of
persistent viral infection and other disorders of T cell suppres-
sion or enhancement.
EXPERIMENTAL PROCEDURES
Mice and Viruses
C57BL/6J male mice (6–8 weeks of age) were obtained from the rodent
breeding colony at The Scripps Research Institute, while IFNb/ and ifnar/
mice were bred and maintained in the animal facility at the same institute.
IFNb/ were obtained from Dr. Eleanor Fish (University of Toronto). All mice
were maintained in pathogen-free conditions, and handling conformed to
the requirements of the NIH and The Scripps Research Institute Animal
Research Committee. LCMV Cl-13 was grown, stored, and quantified
according to previously publishedmethods (Borrow et al., 1995). Mice were in-
fected by intravenous injection of 2 3 106 plaque-forming units (pfu) of virus.
For quantification of viremia, blood was drawn from the retro-orbital sinus un-
der isoflurane anesthesia. Serum was separated by low-speed centrifugation
to remove red and white blood cells. Viral loads were thenmeasured using pla-
que assays on VeroE6 cells (Ahmed et al., 1984). Tissues (spleen, lung, liver,
and kidney) were harvested from euthanized mice and frozen at 80C. At
the time of the assay, tissues were thawed, weighed, and homogenized in
media to 10% w/v, clarified by low-speed centrifugation, and then utilized in
plaque assays as previously described (Ahmed et al., 1984).
Antibody Treatments
C57BL/6Jmice were intraperitoneally inoculatedwith either 250–600 mg of anti-
IFNb antibody (clone HDb-4A7) (K.C.F.S., H.M. Lazear, M.S. Diamond, and
R.D.S., unpublished data), 1 mg of anti-IFNa (clone TIF-3C5) (K.C.F.S., H.M.
Lazear, M.S. Diamond, and R.D.S., unpublished data), 1 mg of anti-IFNAR1
antibody (clone MAR1-5A3; Leinco Technologies) (Sheehan et al., 2006), or a
mouse IgG1 isotype control (clone MOPC21; Bio X Cell) 1 day prior to virus
infection. Effective dose of anti-IFNb antibody was determined by titration for
each new lot of antibody.
Tissue Processing and Cell Surface Staining
Spleens were harvested at the indicated time points and processed into sin-
gle-cell suspension through a 70-mm cell strainer (Corning Life Sciences)
before lysing erythrocytes with ammonium chloride. Splenocytes were stained
with anti-murine antibodies against markers for T cell subsets or macrophage
and DC subsets (Text S1). For tetramer staining, splenocytes were incubated
with either MHC class I tetramers for DbGP33-41 and NP396-404 or GP61-77 (Text
S1). Intracellular staining for the LCMV NP antigen was done by incubating the
Alexa Fluor 488 conjugated VL-4 antibody (Bio X Cell; 1:100 dilution) in BD per-
meabilization solution (BD Biosciences, PharMingen) and analyzed by flow
cytometry.
T Cell Cytokine Responses and Flow Cytometry
Splenocytes were stimulated with 2 mg/ml of MHC class I restricted LCMV-
GP33–41 and NP396-404 peptide or 10 mg/ml of MHC class II restricted LCMV-
GP61-77 peptide (> 99% pure; American Peptide and The Scripps Research
Institute, Center for Protein Science, La Jolla) for 1 hr in the absence of brefel-
din A and then 5 hr in the presence of 4 mg/ml brefeldin A (Sigma, St. Louis)
at 37C. Cells were fixed, permeabilized with 2% saponin, and stained with
antibodies to mouse IFN-g (XMG1.2), TNF-a (MP6-XT22), and IL-2 APC
(JES6-5H4). Flow cytometric analysis was performed on a BD LSR II (Becton
Dickinson), and data were analyzed using FlowJo (Tree Star). Absolute number
of cells was determined by multiplying the frequency of specific cell popula-
tions by the total number of viable cells.
Tissue Staining and Imaging
For H&E staining, spleens were fixed overnight in formaldehyde/zinc fixative,
paraffin embedded, sectioned, and stained using a standard H&E protocol.ost & Microbe 17, 653–661, May 13, 2015 ª2015 Elsevier Inc. 659
For immunofluorescence, spleens were snap frozen on dry ice in OCT (Tissue-
Tek) and stored at80C. Frozen sections (6 mm)were cut, fixedwith 4%para-
formaldehyde for 20 min, blocked with 10% FBS, and stained overnight at 4C
with either guinea pig antibody to LCMV (1:1,000 dilution), rabbit anti-mouse
CD3 antibody (Abcam, 1:200), rat anti-mouse MOMA-1 antibody (Abcam,
1:200), or rat anti-ER-TR7 antibody (Abcam, 1:250). Tissues were washed,
incubated at 1 hr with Alexa Fluor 488-conjugated antibody to guinea pig
IgG (1:200, Invitrogen), Alexa Fluor 568-conjugated anti-rabbit IgG (1:200, In-
vitrogen), and Alexa Fluor 488- or 568-conjugated antibody to rat IgG (1:200,
Invitrogen), washed, stained with 4,6-diamidino-2-phenylindole (DAPI), and
mounted using Prolong Gold mounting medium (Life Technologies). Images
were taken with a Zeiss Axiovert S100 immunofluorescence microscope fitted
with an automated XY stage, an Axiocam color digital camera, and 53, 103,
and 203 objectives.
Quantification of Cytokine and Chemokine Levels
IFN-I levels were quantified using VeriKine Mouse Interferon-Alpha and Inter-
feron-Beta ELISA Kits (R&D Systems). IL-10 was quantified using the IL-10
Quantikine Kits (R&D Systems) according to the manufacturer’s instructions.
Statistics
One-way ANOVA with Tukey’s post test and Student’s t test was calculated
using GraphPad Prism 5, when appropriate, to determine significance, which
was set at 5%.
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